ProCE Banner Activity

Durability of Response to Axicabtagene Ciloleucel in Patients With Refractory DLBCL: Long-term Follow-up of Phase II ZUMA-1 Trial

Slideset Download
Conference Coverage
Extended follow-up of this pivotal phase II trial suggests 3-month response to axi-cel may be prognostic of long-term remissions.

Released: June 05, 2018

Expiration: June 04, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen